{"schema_version":"secwatch.filing_event.v1","accession":"0000014272-24-000145","form_type":"8-K","ticker":"BMY","cik":"0000014272","company_name":"BRISTOL MYERS SQUIBB CO","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.425668+00:00","generated_at":"2026-05-30T07:22:06.964285+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bristol Myers Q3 2024 revenue $11.9B (+8% YoY); raises full-year guidance, Cobenfy approved","bullets":["Q3 2024 revenues $11.9B, up 8% (+10% ex-FX); GAAP EPS $0.60, Non-GAAP EPS $1.80.","Growth Portfolio revenues $5.8B, up 18% (+20% ex-FX).","U.S. approval of Cobenfy (schizophrenia) achieved in Q3.","Raising 2024 revenue guidance to ~+5% (+6% ex-FX); Non-GAAP EPS range raised to $0.75–$0.95.","Net impact of acquired IPRD charges and licensing income reduced EPS by $0.09 on both GAAP and Non-GAAP."],"urls":{"canonical":"https://secwatch.observer/filing/0000014272-24-000145","json":"https://secwatch.observer/filing/0000014272-24-000145.json","markdown":"https://secwatch.observer/filing/0000014272-24-000145.md","text":"https://secwatch.observer/filing/0000014272-24-000145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/14272/000001427224000145/0000014272-24-000145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/14272/000001427224000145/bmy-20241031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:22:06.964285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}